Literature DB >> 21036553

Assessment of social anxiety in first episode psychosis using the Liebowitz Social Anxiety scale as a self-report measure.

K L Romm1, J I Rossberg, A O Berg, C F Hansen, O A Andreassen, I Melle.   

Abstract

OBJECTIVE: Social anxiety is a common problem in psychotic disorders. The Liebowitz Social Anxiety Scale, Self-Rating version (LSAS-SR) is a widely used instrument to capture different aspects of social anxiety, but its psychometric properties have not been tested in this patient group. The aims of the present study were to evaluate the psychometric properties of the LSAS-SR in patients with first episode psychosis, to investigate whether it differentiated between active and passive social withdrawal and to test which clinical factors contributed to current level of social anxiety.
METHOD: A total of 144 first episode psychosis patients from the ongoing Thematically Organized Psychosis (TOP) study were included at the time of first treatment. Diagnoses were set according to the Structured Clinical Interview (SCID-1) for DSM-IV. A factor analysis was carried out and the relationship of social anxiety to psychotic and general symptomatology measured by the Positive and Negative Syndrome Scale (PANSS) was evaluated. Possible contributors to social anxiety were analyzed using multiple hierarchic regression analysis.
RESULTS: The factor analysis identified three subscales: public performance, social interaction and observation. All three subscales showed satisfactory psychometric properties, acceptable convergent and discriminate properties, and confirmed previous findings in social anxiety samples. Self-esteem explained a significant amount of the variance in social anxiety, even after adjusting for the effects of delusions, suspiciousness and depression.
CONCLUSION: The study shows that the LSAS-SR can be used in this patient group, that social anxiety is strongly related to both behavioral social avoidance and to self-esteem. The results support the use of this measure in assessment of social anxiety in both clinical settings and in research.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21036553     DOI: 10.1016/j.eurpsy.2010.08.014

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  6 in total

1.  The factor structure of the Liebowitz Social Anxiety Scale for Children and Adolescents: development of a brief version.

Authors:  Iris Shachar; Idan M Aderka; Eva Gilboa-Schechtman
Journal:  Child Psychiatry Hum Dev       Date:  2014-06

2.  Psychometric properties of an innovative self-report measure: The Social Anxiety Questionnaire for adults.

Authors:  Vicente E Caballo; Benito Arias; Isabel C Salazar; María Jesús Irurtia; Stefan G Hofmann
Journal:  Psychol Assess       Date:  2015-03-16

3.  Ten-year audit of clients presenting to a specialised service for young people experiencing or at increased risk for psychosis.

Authors:  Agatha M Conrad; Terry J Lewin; Ketrina A Sly; Ulrich Schall; Sean A Halpin; Mick Hunter; Vaughan J Carr
Journal:  BMC Psychiatry       Date:  2014-11-18       Impact factor: 3.630

4.  Psychometric properties of the Persian version of social anxiety questionnaire for adults (SAQ-A30).

Authors:  Mahdieh Mosarezaee; Azadeh Tavoli; Ali Montazeri
Journal:  Health Qual Life Outcomes       Date:  2020-06-29       Impact factor: 3.186

5.  Psychometric properties of the Liebowitz Social Anxiety Scale in a large cross-cultural Spanish and Portuguese speaking sample.

Authors:  Vicente E Caballo; Isabel C Salazar; Víctor Arias; Stefan G Hofmann; Joshua Curtiss
Journal:  Braz J Psychiatry       Date:  2018-10-11       Impact factor: 2.697

6.  Psychometric validation study of the liebowitz social anxiety scale - self-reported version for Brazilian Portuguese.

Authors:  Larissa Forni dos Santos; Sonia Regina Loureiro; José Alexandre de Souza Crippa; Flávia de Lima Osório
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.